Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients

Creators: Ilie, M.; Long, E.; Hofman, Véronique; Dadone, B.; Marquette, H.; Mouroux, J.; Vignaud, Jean; Begueret, H.; Merlio, J. P.; Capper, D.; von Deimling, A.; Emile, J.; Hofman, Paul

Others:: Institut de Recherche sur le Cancer et le Vieillissement (IRCAN) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS) ; COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA); Human Biobank CHUN ; Hôpital Pasteur [Nice] (CHU); L'Association pour la Recherche contre le Cancer (ARC); Laboratoire de Pathologie Clinique et Expérimentale. Hôpital Pasteur [Nice] ; Hôpital Pasteur [Nice] (CHU); Service de Chirurgie Thoracique [Pasteur-Nice] ; Hôpital Pasteur [Nice] (CHU); Service de Pathologie [CHRU Nancy] ; Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy); Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE) ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL); Département de pathologie [Hôpital Haut Lévêque] ; Hôpital Haut-Lévêque [CHU Bordeaux] ; CHU Bordeaux [Bordeaux]-CHU Bordeaux [Bordeaux]; Ruprecht Karls University Heidelberg; German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ); Service de pathologie [CHU Ambroise Paré] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP]; Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie (BECCOH) ; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Saclay

Description

BACKGROUND:Non-small-cell lung carcinoma (NSCLC) patients with a BRAF(V600E) mutation benefit from targeted therapy. The usefulness of immunohistochemistry (IHC) as an alternative approach for the detection of BRAF(V600E) in NSCLC patients has not been evaluated until now. This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAF(V600E) in primary lung adenocarcinoma.PATIENTS AND METHODS:BRAF mutations were analysed by DNA sequencing of a Caucasian subpopulation of selected 450 of 1509 (30%) EGFR, KRAS, PI3KA, Her2 and EML4-ALK wild-type (wt) primary lung adenocarcinomas. Detection of the BRAF(V600E) mutation was carried out by IHC using the VE1 clone antibody and compared with the results of other molecular methodologies.RESULTS:Of 450 (9%) of tumours, 40 harboured a BRAF mutation, which corresponded to either a BRAF(V600E) or a non-BRAF(V600E) mutation in 21 of 450 (5%) and 19 of 450 (4%) cases, respectively. The IHC VE1 assay was positive in 19 of 21 (90%) BRAF(V600E)-mutated tumours and negative in all BRAF(nonV600E)-mutated tumours.CONCLUSION:IHC using the VE1 clone is a specific and sensitive method for the detection of BRAF(V600E) and may be an alternative to molecular biology for the detection of mutations in NSCLC.

Abstract

International audience

Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients

Description

Abstract

Additional details